Extension Study for Participants in Trials That Include Pembrolizumab.

Phase 3

• Conditions: C34 Malignant neoplasm of bronchus and lung; Malignant neoplasm of bronchus and lung

• Registration Number: PER-026-22
• Lead Sponsor: Merck Sharp & Dohme LLC., (una subsidiaria de Merck & Co. Inc.)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2023-09-14
• Last Update Posted: 20 August 2024

Recruitment & Eligibility

• Status: In enrollment
• Sex: All
• Target Recruitment: 0

Inclusion Criteria

Participants are currently enrolled in MSD-sponsored pembrolizumab trials and are receiving trial treatment or in a follow-up phase at the time KN-587 is open. Participants must be from MSD-sponsored pembrolizumab parent trials established by the Sponsor as KN-587 transition-ready.
NOTE: Parent trial participants in survival follow-up who are not eligible to receive treatment in KN-587 may complete transitioning to KN-587 after close-out of the parent MSD trial.

The participant (or legally acceptable representative if applicable) provides informed consent for the trial and agrees to follow study procedures.

Exclusion Criteria

There are no exclusion criteria to participate in KN-587.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Kaplan-Meier method<br> NAME OF THE RESULT: Overall Survival (OS)<br> PERIOD OF TIME WHERE TE MEASUREMENT WILL BE CONDUCTED AND WHICH WILL ALLOW OBTAINING THE<br> PRIMARY RESULT: From randomization or start of trial treatment for non-randomized<br>participants (on the parent trial) to death due to any cause.